Literature DB >> 23161752

The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma.

Min Ji Jeon1, Jong Ho Yoon, Ji Min Han, Ji Hye Yim, Suck Joon Hong, Dong Eun Song, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Won Bae Kim.   

Abstract

OBJECTIVE: The presence of central neck lymph node (LN) metastases (defined as pN1a according to Tumor Node Metastasis classification) in papillary thyroid cancer (PTC) is known as an independent risk factor for recurrence. Extent of LN metastasis and the completeness of removal of metastatic LN must have an impact on prognosis but they are not easy to measure. Moreover, the significance of the size of metastatic tumors in LNs has not been clarified. This study was to evaluate the impact of the extent of LN metastasis and size of metastatic tumors on the recurrence in pathological N1a PTC.
DESIGN: This retrospective observational cohort study enrolled 292 PTC patients who underwent total thyroidectomy with central neck dissection from 1999 to 2005. LN ratio was defined as the number of metastatic LNs divided by the number of removed LNs, which was regarded as variable reflecting both extent of LN metastasis and completeness of resection, and LN size as the maximal diameter of tumor in metastatic LN.
RESULTS: The significant risk factors for recurrence in univariate analysis were large primary tumor size (defined as larger than 2 cm), high LN ratio (defined as higher than 0.4), and presence of macrometastasis (defined as larger than 0.2 cm). Age, sex, clinical node status, and microscopic perithyroidal extension had no effect on recurrence. In multivariate analysis, high LN ratio and presence of macrometastasis were independent risk factors for recurrence.
CONCLUSION: LN ratio and size of metastatic nodes had a significant prognostic value in pathological N1a PTC. We suggest that risk stratification of pathological N1a PTC according to the pattern of LN metastasis such as LN ratio and size would give valuable information to clinicians.

Entities:  

Mesh:

Year:  2013        PMID: 23161752     DOI: 10.1530/EJE-12-0744

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  28 in total

1.  Macrometastasis in Papillary Thyroid Cancer Patients is Associated with Higher Recurrence in Lateral Neck Nodes.

Authors:  Soo Young Kim; Bup-Woo Kim; Ju Yeon Pyo; Soon Won Hong; Hang-Seok Chang; Cheong Soo Park
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

2.  Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary Thyroid Cancer.

Authors:  Laura Y Wang; Frank L Palmer; Iain J Nixon; R Michael Tuttle; Jatin P Shah; Snehal G Patel; Ashok R Shaha; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2015-02-10       Impact factor: 5.344

3.  Role of RAI in the management of incidental N1a disease in papillary thyroid cancer.

Authors:  Laura Y Wang; Frank L Palmer; Jocelyn C Migliacci; Iain J Nixon; Ashok R Shaha; Jatin P Shah; Robert Michael Tuttle; Snehal G Patel; Ian Ganly
Journal:  Clin Endocrinol (Oxf)       Date:  2015-07-03       Impact factor: 3.478

4.  Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma.

Authors:  J-W Feng; X-H Yang; B-Q Wu; D-L Sun; Y Jiang; Z Qu
Journal:  Clin Transl Oncol       Date:  2019-03-16       Impact factor: 3.405

Review 5.  Nodal metastases in thyroid cancer: prognostic implications and management.

Authors:  Laura Y Wang; Ian Ganly
Journal:  Future Oncol       Date:  2016-03-07       Impact factor: 3.404

6.  Histopathological Evidence of Lymph Node Metastasis in Papillary Thyroid Carcinoma.

Authors:  Nuray Can; Ebru Tastekin; Filiz Ozyilmaz; Yavuz Atakan Sezer; Sibel Guldiken; Necdet Sut; Nurtac Sarikas; Fulya Oz Puyan; Beril Guler; Semra Ayturk; Mehmet Celik
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

Review 7.  The pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma.

Authors:  Anthony R Glover; Justin S Gundara; Olov Norlén; James C Lee; Stan B Sidhu
Journal:  Gland Surg       Date:  2013-11

8.  High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?

Authors:  Lan Wei; Lin Bai; Lina Zhao; Tianyu Yu; Qingjie Ma; Bin Ji
Journal:  World J Surg       Date:  2019-05       Impact factor: 3.352

9.  Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.

Authors:  Amir Sabet; Ina Binse; Hong Grafe; Samer Ezziddin; Rainer Görges; Thorsten D Poeppel; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-27       Impact factor: 9.236

10.  Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.

Authors:  Young Woo Chang; Hwan Soo Kim; Seung Pil Jung; Hoon Yub Kim; Jae Bok Lee; Jeoung Won Bae; Gil Soo Son
Journal:  Int J Clin Oncol       Date:  2016-02-02       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.